The German Chemical Society awarded ETH Zurich professor Helma Wennemers the Emil Fischer Medal, making her the first woman to receive the prize in its more than century-long history. Established in 1912 for Emil Fischer's sixtieth birthday, the medal honors outstanding organic chemistry, and the…
The German Chemical Society GDCh has awarded the Emil Fischer Medal to Helma Wennemers, Professor of Organic Chemistry at ETH Zurich, for her research on synthetic peptides. Wennemers is the first woman to receive the medal in its more than century-long history. The medal, which the GDCh awards every two years for outstanding achievement in organic chemistry, will be presented on September 7, 2026, at the 24th ORCHEM conference at the University of Freiburg.
The honor lands on a field that has spent decades in the shadow of its larger cousins. The GDCh's recognition highlights synthetic peptides as functional catalysts capable of tasks normally reserved for large macromolecules such as enzymes and antibodies. That is the core of the citation given Wennemers, and it marks a shift in how mainstream chemistry institutions classify peptide science: not merely structural motifs that mimic parts of proteins, but sequence-defined molecules with their own catalytic, biological, and materials functions.
"It is a great honor to receive the Emil Fischer Medal, named after the father of peptide chemistry," Wennemers said. The namesake gives the award its weight. Emil Fischer is considered the father of peptide chemistry and received the 1909 Nobel Prize in Chemistry for work on sugars and purines. The award therefore connects today's synthetic peptide chemistry to the lineage that began with Fischer's studies of amino acids and peptides more than a century ago.
Carl Duisberg established the Emil Fischer Medal in 1912 to mark Emil Fischer's sixtieth birthday. Fischer had won the Nobel Prize three years earlier, and the medal was conceived as a way to honor the leading figures of organic chemistry in his name. The GDCh has awarded it every two years since, with the result that the roll of recipients spans more than a century of organic chemistry.
The 2026 presentation will take place during the 24th ORCHEM conference, which runs September 7 through 9 at the University of Freiburg. The conference is organized by the Liebig Association for Organic Chemistry, a GDCh division that organizes the gathering. The setting matters: ORCHEM is a general organic chemistry meeting, not a peptide symposium. Wennemers's medal will be presented in front of synthetic and physical organic chemists whose work often has little direct relation to hers.
The award has been announced ahead of the ceremony. As of the GDCh's statement, the presentation is scheduled for September 7, 2026, and has not yet occurred. That pattern is standard for prizes, yet it carries a caveat: the honor has been decided, but the ceremony is pending. The announcement itself, however, is unambiguous. Wennemers is the first woman selected for the medal since 1912.
The scientific basis of the medal is a body of work showing that tripeptides, three amino acids long, can act as asymmetric catalysts in minute quantities. Enzymes achieve stereoselective bond formation by folding large polypeptide chains into active sites. A tripeptide has no folded structure to speak of, yet it can accelerate a reaction and control which enantiomer is formed. The mechanism parallels organocatalysis: the N-terminal primary amine condenses with a carbonyl substrate to form an enamine, a nucleophilic intermediate that attacks an electrophile. The remaining side chains surround the reactive center and bias the approach of the incoming partner, so one product configuration dominates.
The GDCh's citation emphasizes that these small catalysts enable continuous multigram-scale synthesis in flow reactors. Flow chemistry changes the economics of peptide catalysis. A soluble or immobilized tripeptide can be pumped through a reactor with substrate streams, producing product continuously rather than in batch flasks. Multigram scale is the range that matters for process chemistry: enough material for medicinal chemistry campaigns and early development, produced without a large enzyme or a transition metal. The absence of metals from a synthetic route has a practical advantage in pharmaceutical manufacturing, where residual metal limits in drug substances are tightly controlled.
"This recognition of my laboratorys long-standing interests of peptides in stereoselective catalysis, chemical biology, and supramolecular chemistry means a lot," Wennemers said. The sentence maps the three research axes that the medal citation draws on. Stereoselective catalysis is the best developed: a tripeptide carrying a few functional residues can rival larger organocatalysts in enantioselectivity, and the sequence format makes catalyst optimization a matter of combinatorial synthesis rather than total redesign.
The chemical biology arm of the laboratory produced a probe that detects collagen remodeling in tumors and scar tissue. Collagen is the main structural protein of the extracellular matrix, and its breakdown and rebuilding are central to how tumors invade surrounding tissue and how wounds heal into scars. A probe that reports on that remodeling has obvious diagnostic value. ETH Zurich named the probe its most important invention of 2020, a university-level recognition that flagged its translational potential.
The supramolecular arm includes a supramolecular weave, a material built from interlocking peptide assemblies, and functional synthetic collagen: designed sequences that assemble into collagen-like triple helices with useful mechanical or biological properties. Both projects treat the peptide chain as an information-carrying polymer, where the side-chain sequence dictates how chains recognize one another and fold into larger structures. That is the same principle that governs natural collagen, transferred to simplified, fully synthetic systems that can be produced and modified at will.
Cell-penetrating peptides round out the portfolio. These are short sequences able to cross lipid membranes and carry attached cargo into cells, addressing the delivery problem that blocks many therapeutic molecules: they act inside cells, but cannot get there on their own. The common thread across catalysis, materials, and chemical biology is that a handful of amino acids can encode function. The GDCh's emphasis on peptides as substitutes for large macromolecules applies as much to the weave and the collagen mimics as to the catalysts.
The Emil Fischer Medal is not the first major prize for this program. In 2023, Wennemers received the American Peptide Society's Vincent du Vigneaud Award and gave an award lecture at that year's American Peptide Symposium in Scottsdale. That award comes from the peptide research community itself, the people best positioned to judge the technical content of the work. In May, the Saxon Academy of Sciences awarded her the Wilhelm Ostwald Medal; the GDCh's statement notes the award arrived in May but does not give its year.
The pattern across these honors is one of climbing institutional reach. The Vincent du Vigneaud Award recognized contributions within peptide chemistry. The Wilhelm Ostwald Medal, named for a physical chemist and philosopher of science, extends into the German scientific academies. The Emil Fischer Medal, from the GDCh, places the work squarely within the general canon of organic chemistry. Each step widens the audience being told to take small peptides seriously.
"Many thanks to the GDCh and a heartfelt thank you to all my wonderful co-workers, both past and present," Wennemers said. The acknowledgment points to a pragmatic fact about the field: tripeptide catalysis and designed collagen require the iterative labor of many hands, since each sequence variant is a separate synthesis, purification, and assay.
For researchers, the award functions as institutional certification that short peptides can be primary tools rather than model compounds. The practical consequences are concrete. Tripeptide catalysts can be synthesized by standard solid-phase methods, which means they can be produced as libraries and screened for activity against a reaction of interest. Their small size makes them inexpensive relative to enzymes, and their sequence space is vast: even a three-residue peptide built from the 20 canonical amino acids has 8,000 possible sequences, and the count grows with noncanonical residues and modifications.
For clinicians and the supply chain, the implications are more distant but real. The collagen-remodeling probe is a diagnostic concept in search of a clinical pathway; the cell-penetrating peptides are delivery vehicles at the same early stage. The flow reactor work is the closest to industrial adoption, because it changes how a catalytic peptide would be supplied and used: continuously, in a reactor, rather than as a batch reagent. Peptide manufacturers who can deliver defined sequences at multigram scale with reproducible purity are the natural suppliers for that model. Catalyst recovery and reuse become process design questions rather than research questions.
The first-woman status matters beyond symbolism. A century of history is a long record, and the breach of that record by a peptide chemist sends two signals at once: that the mainstream establishment values the field, and that the field's most public honors are no longer closed to women. Award records shape who can imagine themselves in a discipline, and the Emil Fischer Medal has just changed its own history.
The GDCh's announcement, taken alone, leaves several specifics unspecified. It does not give the amino acid sequences of the tripeptide catalysts, nor does it quantify the loadings behind the phrase "minute quantities" or the productivity that multigram-scale flow synthesis represents. It does not name the year of the Wilhelm Ostwald Medal; the Saxon Academy of Sciences honor is referenced only as May. These omissions do not weaken the award, but they define the limit of what the announcement itself establishes.
The award also does not validate any clinical application. ETH Zurich's 2020 designation of the collagen-remodeling probe as its most important invention of the year is a technology-transfer signal, not a regulatory milestone. No trial results, product approvals, or clinical efficacy data are attached to the announcement. The cell-penetrating peptides, the supramolecular weave, and the functional synthetic collagen are research-stage achievements, impressive as science but unproven as medicines or as materials in use.
What would resolve the open questions is straightforward. The award lecture in Freiburg is a natural venue for Wennemers to lay out the catalyst structures and reaction scope. The GDCh's formal citation, the laboratory's primary papers, and a dated statement from the Saxon Academy of Sciences would fix the remaining details. Until then, the record that matters is unambiguous: for the first time in more than a century, the Emil Fischer Medal will be presented to a woman, and the science on the table is the chemistry of small peptides.
Related reading: Cyclized Cecropin A Peptide Reaches Phase IIa for CRAB Pneumonia, Copenhagen's New Protein Design Center Opens With 109 Million Dollar Grant, FDA Panel Backs Six Unapproved Peptides for 503A Compounding List, GLP-1 multi-target therapies and manufacturing near 2025 milestones.